Literature DB >> 22452402

Active targeting strategies for anticancer drug nanocarriers.

Livia Basile1, Rosario Pignatello, Catherine Passirani.   

Abstract

Chemotherapy at present remains the main form of treatment for cancer, though there is no clinically available antineoplastic drug that acts selectively on the tumor mass. For this reason, the scientific research is focused towards the development of novel cancer therapies and drug delivery strategies, like drug targeting, that would enhance the therapeutic efficacy of drugs while reducing their side toxicity. This review describes tree types of nanoparticles used in active targeting for cancer treatment: liposomes, lipid and polymer nanoparticles, and micelles. The opportunities and challenges achieved by the proposed strategies of active targeting have been highlighted, as well as the necessity to conciliate the targeting efficiency of drug nanocarriers with their longevity in the bloodstream.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22452402     DOI: 10.2174/156720112800389089

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  8 in total

Review 1.  Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors:  Satish K Singh; Donna L Luisi; Roger H Pak
Journal:  Pharm Res       Date:  2015-05-19       Impact factor: 4.200

2.  Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.

Authors:  Sivakumar Vijayaraghavalu; Josephine Kamtai Dermawan; Venugopalan Cheriyath; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

3.  Synthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic properties.

Authors:  Rosario Pignatello; Maria Grazia Sarpietro; Francesco Castelli
Journal:  J Funct Biomater       Date:  2012-01-19

4.  Development of Novel Pyridine-Thiazole Hybrid Molecules as Potential Anticancer Agents.

Authors:  Iryna Ivasechko; Ihor Yushyn; Piotr Roszczenko; Julia Senkiv; Nataliya Finiuk; Danylo Lesyk; Serhii Holota; Robert Czarnomysy; Olga Klyuchivska; Dmytro Khyluk; Nataliya Kashchak; Andrzej Gzella; Krzysztof Bielawski; Anna Bielawska; Rostyslav Stoika; Roman Lesyk
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

Review 5.  Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer.

Authors:  Joshua McCarroll; Joann Teo; Cyrille Boyer; David Goldstein; Maria Kavallaris; Phoebe A Phillips
Journal:  Front Physiol       Date:  2014-01-24       Impact factor: 4.566

6.  Paclitaxel-incorporated nanoparticles using block copolymers composed of poly(ethylene glycol)/poly(3-hydroxyoctanoate).

Authors:  Hyun Yul Kim; Je Ho Ryu; Chong Woo Chu; Gyung Mo Son; Young-Il Jeong; Tae-Won Kwak; Do Hyung Kim; Chung-Wook Chung; Young Ha Rhee; Dae Hwan Kang; Hyung Wook Kim
Journal:  Nanoscale Res Lett       Date:  2014-09-24       Impact factor: 4.703

Review 7.  Mir-34: a new weapon against cancer?

Authors:  Gabriella Misso; Maria Teresa Di Martino; Giuseppe De Rosa; Ammad Ahmad Farooqi; Angela Lombardi; Virginia Campani; Mayra Rachele Zarone; Annamaria Gullà; Pierosandro Tagliaferri; Pierfrancesco Tassone; Michele Caraglia
Journal:  Mol Ther Nucleic Acids       Date:  2014-09-23       Impact factor: 10.183

8.  A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma.

Authors:  Gary A Clawson; Thomas Abraham; Weihua Pan; Xiaomeng Tang; Samuel S Linton; Christopher O McGovern; Welley S Loc; Jill P Smith; Peter J Butler; Mark Kester; James H Adair; Gail L Matters
Journal:  Nucleic Acid Ther       Date:  2016-10-18       Impact factor: 5.486

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.